Cancer Cell· Xiuning Le, Jie Wang, Yan Yu, Yanqiu Zhao, David Planchard, Bo Gao, Alexander Spira, Jingling Liu, Xingya Li, Shirish Gadgeel, Natasha Leighl, Junqiang Zhang, Hidetoshi Hayashi, Makoto Nishio, Julien Mazieres, Adrianus Johannes de Langen, Maurice Pérol, Kiyotaka Yoh, Martin D. Forster, Yasushi Goto, Maria de Miguel Luken, Fernando Fabio Franco Perez, Quincy Chu, Sagun Parakh, Monique B. Nilsson, Yong Jiang, Tianhua Hu, Cunlin Wang, Nichole Baio, Luna Musib, Zineb Mounir, Marcin Kowanetz, Shirley Wang, Steven Yea, Jerry Hsu, Stuart Lutzker, John V. Heymach, Oscar Juan-Vidal, Jonathan W. Riess·· 22 小时前AI 评分36
Firmonertinib用于携带EGFR P环和αC螺旋压缩型突变的晚期非小细胞肺癌
Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations
AI 导读
在Ib期FURTHER临床试验中，firmonertinib治疗携带EGFR PACC突变的晚期非小细胞肺癌患者，显示出显著且持久的缓解，不良反应可耐受。这种小分子TKI具有抑制EGFR PACC突变的独特结构，研究结果支持进一步开展大型随机临床试验。
来源：Cancer Cell · cell.com